Dr. EL-Habib Dakir
Institute of Cancer Therapeutics University of Bradford, UK.
EL-Habib Dakir is Medical Scientist at Institute of Cancer Therapeutics, Bradford University in United Kingdom, he has more than 16 years experience as a Postdoctoral Scientist. Dr Dakir was invited as visiting scientist at National Institutes of Health (NIH), National Cancer Institute, USA where he developed genetically modified mice models (lung cancer) for cancer study and chemotherapy, he has broad experience in cancer biology, cell therapy, carcinogenesis and drugs activated cancer cell death, apoptosis, drug development and validations in in vitro and in xenograft mouse models, he received NIH-Award Excellence in Biomedical Research in 2007. His lectures are distributed in molecular carcinogenesis & mutagenesis, apoptosis & cancer therapy, preclinical models of human cancer, molecular genetics, biochemistry, cancer pharmacology, experimental pathology, and cell molecular biology. Dr Dakir received his Ph.D. in Molecular Genetics at Leon University, Spain; MSc in Genetics in Advanced Mediterranean Studies at Zaragoza Institute, Spain. He is member of American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO) and International Association of Study of Lung Cancer (IASLC), He is currently a member of the board of reviewing editors of the new cancer-prime journal, annals of mutagenesis and Journal of Medical Oncology and Therapeutics; Dr EL-Habib Dakir he participates in various national and international cancer research projects and presented his work at national and international conferences.
Apoptosis, Cell Death & Proliferation Mechanisms
Circulating Tumor Cells (CTCs)
Gene Expressions & Genomics;
Drugs & Genotoxicity
Tobacco Carcinogenesis, Drug validations in vitro & in vivo, in vivo mouse models (GEM, Xenograft)
Confocal microscopy, Electron Microscopy (TEM & SEM).